The Oncologist · 2019 · 12 citations · 23 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyBiliary Tract CancerChemotherapy Toxicity ManagementToxicity Management5-Fluorouracil Therapy5-Fluorouracil TreatmentPhase Ii InvestigationSingle-arm Trials
LESSONS LEARNED: Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors. FTD/TPI has an acceptable safety profile and should be studied further in patients with advanced biliary tract carcinoma after progression on standard first-line therapy. BACKGROUND: Patients with advanced biliary tract carcinoma (BTC) refractory to first-line therapy lack an established second-line option. Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC. METHODS: Patients with advanced BTC previously treated with at least one line of chemotherapy were enrolled and treated with FTD/TPI until disease progression or unacceptable toxicity. The primary endpoint target was to have at least 6 patients who were progression free and alive at 16 weeks among 25 evaluable patients. Secondary endpoints included overall survival (OS), overall response rate (ORR), progression-free survival (PFS), and toxicity. RESULTS: Of 27 evaluable patients, 59.3% received at least three prior lines of therapy, and 81.5% had previous exposure to fluoropyrimidine. Eight (32%, 95% confidence interval [CI], 14.9%-53.5%) patients were progression free at 16 weeks in the primary analysis population (n = 25), which met the predefined efficacy criteria. Median PFS and OS were 3.8 (95% CI, 2-5.8 months) and 6.1 (95% CI, 4.4-11.4 months) months, respectively. No objective responses were seen. There were no unexpected safety signals noted. CONCLUSION: FTD/TPI demonstrated promising antitumor activity, with acceptable toxicity, in heavily pretreated patients with advanced BTC.
23
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +12
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Yizhou Wang, Jun Li, Yong Xia et al. · Journal of Clinical Oncology · 2013 · 1.1K citations · Full text
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin et al. · The Lancet Oncology · 2018 · 520 citations
Medicine, Oncology, Pharmacology +12
Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · Journal of Clinical Oncology · 2019 · 227 citations
Medicine, Oncology, Chemotherapy +12